Neurocrine Biosciences (NASDAQ:NBIX) (NASDAQ:NBIX) is a biotechnology company dedicated to developing treatments for neurological, endocrine and psychiatric disorders. Headquartered in San Diego, California, Neurocrine focuses on identifying and advancing novel therapeutics that address unmet medical needs in central nervous system conditions. Its core mission is to leverage scientific research in neuropharmacology to bring innovative medicines from discovery through commercialization.
The company’s commercial portfolio includes Ingrezza® (valbenazine), approved for the treatment of tardive dyskinesia, and Orilissa® (elagolix), a therapy for endometriosis and uterine fibroids. Ingrezza has become a standard of care in mitigating involuntary movements associated with certain psychiatric and neurological disorders, while Orilissa offers non-surgical options for women experiencing moderate to severe pain from endometriosis. Beyond these approved products, Neurocrine has built an extensive pipeline featuring late-stage clinical candidates targeting Parkinson’s disease, Huntington’s disease, sleep disorders and psychiatric conditions.
Neurocrine’s research and development efforts are supported by strategic collaborations and partnerships across North America, Europe and Asia. The company maintains a global commercial organization and works closely with regulatory agencies to advance its product candidates through clinical trials. Manufacturing and distribution networks are established to ensure broad patient access, and the company invests in medical affairs and patient support programs that facilitate education, diagnosis and ongoing care within the communities it serves.
Founded in 1992 by a team of neuroscientists, Neurocrine Biosciences has evolved under the leadership of President and Chief Executive Officer Kevin C. Gorman. The executive management team comprises seasoned professionals in research, development and commercial operations, guided by a board of directors with deep expertise in biotechnology and life sciences. With a focus on scientific innovation and patient outcomes, Neurocrine continues to pursue growth through internal discovery and external partnerships, aiming to deliver new therapies that improve quality of life for patients worldwide.
